Items where Funder is Leeds Hospitals Charity.
Up a level1T01-A321
Hassanieh, S., Domingo, E., Blake, A. et al. (16 more authors) (2022) 337P Prediction of poor response to oxaliplatin by an RNA signature derived and validated in colorectal cancer clinical trials. In: Annals of Oncology. ESMO Congress 2022, 09-13 Sep 2022, Paris, France. Elsevier , S691.
Seligmann, JF, Domingo, E, Fisher, D et al. (17 more authors) (2022) The clinical relevance of tumor RAS/TP53 dual mutation in early and metastatic colorectal cancer (CRC). In: 2022 ASCO Annual Meeting, 03-07 Jun 2022, Chicago, Il, USA and Online.
Williams, C. orcid.org/0000-0002-1574-653X, Seligmann, J.F. orcid.org/0000-0003-4379-6005, Guetter, C. et al. (13 more authors) (2021) Artificial intelligence-assisted immunohistochemical (IHC) evaluation of tumor amphiregulin (AREG) and epiregulin (EREG) expression as a combined predictive biomarker for panitumumab (Pan) therapy benefit in RAS wild-type (wt) metastatic colorectal cancer (mCRC): Analysis within the phase III PICCOLO trial. In: Journal of Clinical Oncology. 2021 Gastrointestinal Cancers Symposium, 15-17 Jan 2021, Online. American Society of Clinical Oncology , p. 111.
Platt, JR, Todd, OM orcid.org/0000-0001-7212-8095, Hall, P et al. (14 more authors) (2023) FOxTROT2: innovative trial design to evaluate the role of neoadjuvant chemotherapy for treating locally advanced colon cancer in older adults or those with frailty. ESMO Open, 8 (1). 100642. ISSN 2059-7029
Brown, LC, Graham, J, Fisher, D et al. (15 more authors) (2022) Experiences of running a stratified medicine adaptive platform trial: Challenges and lessons learned from 10 years of the FOCUS4 trial in metastatic colorectal cancer. Clinical Trials, 19 (2). pp. 146-157. ISSN 1740-7745
2012-005111-12
Seligmann, JF, Domingo, E, Fisher, D et al. (17 more authors) (2022) The clinical relevance of tumor RAS/TP53 dual mutation in early and metastatic colorectal cancer (CRC). In: 2022 ASCO Annual Meeting, 03-07 Jun 2022, Chicago, Il, USA and Online.
Seligmann, JF, Domingo, E, Fisher, D et al. (17 more authors) (2022) The clinical relevance of tumor RAS/TP53 dual mutation in early and metastatic colorectal cancer (CRC). In: 2022 ASCO Annual Meeting, 03-07 Jun 2022, Chicago, Il, USA and Online.
Brown, LC, Graham, J, Fisher, D et al. (15 more authors) (2022) Experiences of running a stratified medicine adaptive platform trial: Challenges and lessons learned from 10 years of the FOCUS4 trial in metastatic colorectal cancer. Clinical Trials, 19 (2). pp. 146-157. ISSN 1740-7745
Brown, LC, Graham, J, Fisher, D et al. (15 more authors) (2022) Experiences of running a stratified medicine adaptive platform trial: Challenges and lessons learned from 10 years of the FOCUS4 trial in metastatic colorectal cancer. Clinical Trials, 19 (2). pp. 146-157. ISSN 1740-7745
4616
Hassanieh, S., Domingo, E., Blake, A. et al. (16 more authors) (2022) 337P Prediction of poor response to oxaliplatin by an RNA signature derived and validated in colorectal cancer clinical trials. In: Annals of Oncology. ESMO Congress 2022, 09-13 Sep 2022, Paris, France. Elsevier , S691.
Seligmann, JF, Domingo, E, Fisher, D et al. (17 more authors) (2022) The clinical relevance of tumor RAS/TP53 dual mutation in early and metastatic colorectal cancer (CRC). In: 2022 ASCO Annual Meeting, 03-07 Jun 2022, Chicago, Il, USA and Online.
Williams, C. orcid.org/0000-0002-1574-653X, Seligmann, J.F. orcid.org/0000-0003-4379-6005, Guetter, C. et al. (13 more authors) (2021) Artificial intelligence-assisted immunohistochemical (IHC) evaluation of tumor amphiregulin (AREG) and epiregulin (EREG) expression as a combined predictive biomarker for panitumumab (Pan) therapy benefit in RAS wild-type (wt) metastatic colorectal cancer (mCRC): Analysis within the phase III PICCOLO trial. In: Journal of Clinical Oncology. 2021 Gastrointestinal Cancers Symposium, 15-17 Jan 2021, Online. American Society of Clinical Oncology , p. 111.
Platt, JR, Todd, OM orcid.org/0000-0001-7212-8095, Hall, P et al. (14 more authors) (2023) FOxTROT2: innovative trial design to evaluate the role of neoadjuvant chemotherapy for treating locally advanced colon cancer in older adults or those with frailty. ESMO Open, 8 (1). 100642. ISSN 2059-7029
Brown, LC, Graham, J, Fisher, D et al. (15 more authors) (2022) Experiences of running a stratified medicine adaptive platform trial: Challenges and lessons learned from 10 years of the FOCUS4 trial in metastatic colorectal cancer. Clinical Trials, 19 (2). pp. 146-157. ISSN 1740-7745
5T02 & 4M04/A2001064
Spoletini, G, Gillgrass, L, Pollard, K et al. (5 more authors) (2022) Dose adjustments of Elexacaftor/Tezacaftor/Ivacaftor in response to mental health side effects in adults with cystic fibrosis. Journal of Cystic Fibrosis, 21 (6). pp. 1061-1065. ISSN 1569-1993
9R01/0004
Platt, JR, Todd, OM orcid.org/0000-0001-7212-8095, Hall, P et al. (14 more authors) (2023) FOxTROT2: innovative trial design to evaluate the role of neoadjuvant chemotherapy for treating locally advanced colon cancer in older adults or those with frailty. ESMO Open, 8 (1). 100642. ISSN 2059-7029
A14923
Platt, JR, Todd, OM orcid.org/0000-0001-7212-8095, Hall, P et al. (14 more authors) (2023) FOxTROT2: innovative trial design to evaluate the role of neoadjuvant chemotherapy for treating locally advanced colon cancer in older adults or those with frailty. ESMO Open, 8 (1). 100642. ISSN 2059-7029
A2001317/3U70
Taze, D, Hartley, C, Morgan, AW orcid.org/0000-0003-1109-624X et al. (3 more authors) (2022) Developing consensus in Histopathology: the role of the Delphi method. Histopathology, 81 (2). pp. 159-167. ISSN 0309-0167
A2001693
Downey, C.L. orcid.org/0000-0001-9818-8002, Bainbridge, J., Jayne, D.G. orcid.org/0000-0002-8725-3283 et al. (1 more author) (2023) Impact of in-hospital postoperative complications on quality of life up to 12 months after major abdominal surgery. British Journal of Surgery, 110 (9). pp. 1206-1212. ISSN 0007-1323
BRC
Taze, D, Hartley, C, Morgan, AW orcid.org/0000-0003-1109-624X et al. (3 more authors) (2022) Developing consensus in Histopathology: the role of the Delphi method. Histopathology, 81 (2). pp. 159-167. ISSN 0309-0167
C6003/A10079
Platt, JR, Todd, OM orcid.org/0000-0001-7212-8095, Hall, P et al. (14 more authors) (2023) FOxTROT2: innovative trial design to evaluate the role of neoadjuvant chemotherapy for treating locally advanced colon cancer in older adults or those with frailty. ESMO Open, 8 (1). 100642. ISSN 2059-7029
C6003/A15546
Seligmann, JF, Domingo, E, Fisher, D et al. (17 more authors) (2022) The clinical relevance of tumor RAS/TP53 dual mutation in early and metastatic colorectal cancer (CRC). In: 2022 ASCO Annual Meeting, 03-07 Jun 2022, Chicago, Il, USA and Online.
Williams, C. orcid.org/0000-0002-1574-653X, Seligmann, J.F. orcid.org/0000-0003-4379-6005, Guetter, C. et al. (13 more authors) (2021) Artificial intelligence-assisted immunohistochemical (IHC) evaluation of tumor amphiregulin (AREG) and epiregulin (EREG) expression as a combined predictive biomarker for panitumumab (Pan) therapy benefit in RAS wild-type (wt) metastatic colorectal cancer (mCRC): Analysis within the phase III PICCOLO trial. In: Journal of Clinical Oncology. 2021 Gastrointestinal Cancers Symposium, 15-17 Jan 2021, Online. American Society of Clinical Oncology , p. 111.
C6003/A3830
Hassanieh, S., Domingo, E., Blake, A. et al. (16 more authors) (2022) 337P Prediction of poor response to oxaliplatin by an RNA signature derived and validated in colorectal cancer clinical trials. In: Annals of Oncology. ESMO Congress 2022, 09-13 Sep 2022, Paris, France. Elsevier , S691.
Platt, JR, Todd, OM orcid.org/0000-0001-7212-8095, Hall, P et al. (14 more authors) (2023) FOxTROT2: innovative trial design to evaluate the role of neoadjuvant chemotherapy for treating locally advanced colon cancer in older adults or those with frailty. ESMO Open, 8 (1). 100642. ISSN 2059-7029
C6003/A6407
Williams, C. orcid.org/0000-0002-1574-653X, Seligmann, J.F. orcid.org/0000-0003-4379-6005, Guetter, C. et al. (13 more authors) (2021) Artificial intelligence-assisted immunohistochemical (IHC) evaluation of tumor amphiregulin (AREG) and epiregulin (EREG) expression as a combined predictive biomarker for panitumumab (Pan) therapy benefit in RAS wild-type (wt) metastatic colorectal cancer (mCRC): Analysis within the phase III PICCOLO trial. In: Journal of Clinical Oncology. 2021 Gastrointestinal Cancers Symposium, 15-17 Jan 2021, Online. American Society of Clinical Oncology , p. 111.
Williams, C. orcid.org/0000-0002-1574-653X, Seligmann, J.F. orcid.org/0000-0003-4379-6005, Guetter, C. et al. (13 more authors) (2021) Artificial intelligence-assisted immunohistochemical (IHC) evaluation of tumor amphiregulin (AREG) and epiregulin (EREG) expression as a combined predictive biomarker for panitumumab (Pan) therapy benefit in RAS wild-type (wt) metastatic colorectal cancer (mCRC): Analysis within the phase III PICCOLO trial. In: Journal of Clinical Oncology. 2021 Gastrointestinal Cancers Symposium, 15-17 Jan 2021, Online. American Society of Clinical Oncology , p. 111.
C6003/A7367
Hassanieh, S., Domingo, E., Blake, A. et al. (16 more authors) (2022) 337P Prediction of poor response to oxaliplatin by an RNA signature derived and validated in colorectal cancer clinical trials. In: Annals of Oncology. ESMO Congress 2022, 09-13 Sep 2022, Paris, France. Elsevier , S691.
Seligmann, JF, Domingo, E, Fisher, D et al. (17 more authors) (2022) The clinical relevance of tumor RAS/TP53 dual mutation in early and metastatic colorectal cancer (CRC). In: 2022 ASCO Annual Meeting, 03-07 Jun 2022, Chicago, Il, USA and Online.
Williams, C. orcid.org/0000-0002-1574-653X, Seligmann, J.F. orcid.org/0000-0003-4379-6005, Guetter, C. et al. (13 more authors) (2021) Artificial intelligence-assisted immunohistochemical (IHC) evaluation of tumor amphiregulin (AREG) and epiregulin (EREG) expression as a combined predictive biomarker for panitumumab (Pan) therapy benefit in RAS wild-type (wt) metastatic colorectal cancer (mCRC): Analysis within the phase III PICCOLO trial. In: Journal of Clinical Oncology. 2021 Gastrointestinal Cancers Symposium, 15-17 Jan 2021, Online. American Society of Clinical Oncology , p. 111.
C6003/A7686
Platt, JR, Todd, OM orcid.org/0000-0001-7212-8095, Hall, P et al. (14 more authors) (2023) FOxTROT2: innovative trial design to evaluate the role of neoadjuvant chemotherapy for treating locally advanced colon cancer in older adults or those with frailty. ESMO Open, 8 (1). 100642. ISSN 2059-7029
C7852/A19772
Hassanieh, S., Domingo, E., Blake, A. et al. (16 more authors) (2022) 337P Prediction of poor response to oxaliplatin by an RNA signature derived and validated in colorectal cancer clinical trials. In: Annals of Oncology. ESMO Congress 2022, 09-13 Sep 2022, Paris, France. Elsevier , S691.
Seligmann, JF, Domingo, E, Fisher, D et al. (17 more authors) (2022) The clinical relevance of tumor RAS/TP53 dual mutation in early and metastatic colorectal cancer (CRC). In: 2022 ASCO Annual Meeting, 03-07 Jun 2022, Chicago, Il, USA and Online.
Williams, C. orcid.org/0000-0002-1574-653X, Seligmann, J.F. orcid.org/0000-0003-4379-6005, Guetter, C. et al. (13 more authors) (2021) Artificial intelligence-assisted immunohistochemical (IHC) evaluation of tumor amphiregulin (AREG) and epiregulin (EREG) expression as a combined predictive biomarker for panitumumab (Pan) therapy benefit in RAS wild-type (wt) metastatic colorectal cancer (mCRC): Analysis within the phase III PICCOLO trial. In: Journal of Clinical Oncology. 2021 Gastrointestinal Cancers Symposium, 15-17 Jan 2021, Online. American Society of Clinical Oncology , p. 111.
Platt, JR, Todd, OM orcid.org/0000-0001-7212-8095, Hall, P et al. (14 more authors) (2023) FOxTROT2: innovative trial design to evaluate the role of neoadjuvant chemotherapy for treating locally advanced colon cancer in older adults or those with frailty. ESMO Open, 8 (1). 100642. ISSN 2059-7029
Brown, LC, Graham, J, Fisher, D et al. (15 more authors) (2022) Experiences of running a stratified medicine adaptive platform trial: Challenges and lessons learned from 10 years of the FOCUS4 trial in metastatic colorectal cancer. Clinical Trials, 19 (2). pp. 146-157. ISSN 1740-7745
CRUK 05 06 BUDGET
Platt, JR, Todd, OM orcid.org/0000-0001-7212-8095, Hall, P et al. (14 more authors) (2023) FOxTROT2: innovative trial design to evaluate the role of neoadjuvant chemotherapy for treating locally advanced colon cancer in older adults or those with frailty. ESMO Open, 8 (1). 100642. ISSN 2059-7029
Fund No IT01
Seligmann, JF, Domingo, E, Fisher, D et al. (17 more authors) (2022) The clinical relevance of tumor RAS/TP53 dual mutation in early and metastatic colorectal cancer (CRC). In: 2022 ASCO Annual Meeting, 03-07 Jun 2022, Chicago, Il, USA and Online.
Platt, JR, Todd, OM orcid.org/0000-0001-7212-8095, Hall, P et al. (14 more authors) (2023) FOxTROT2: innovative trial design to evaluate the role of neoadjuvant chemotherapy for treating locally advanced colon cancer in older adults or those with frailty. ESMO Open, 8 (1). 100642. ISSN 2059-7029
Brown, LC, Graham, J, Fisher, D et al. (15 more authors) (2022) Experiences of running a stratified medicine adaptive platform trial: Challenges and lessons learned from 10 years of the FOCUS4 trial in metastatic colorectal cancer. Clinical Trials, 19 (2). pp. 146-157. ISSN 1740-7745
L386
Platt, JR, Todd, OM orcid.org/0000-0001-7212-8095, Hall, P et al. (14 more authors) (2023) FOxTROT2: innovative trial design to evaluate the role of neoadjuvant chemotherapy for treating locally advanced colon cancer in older adults or those with frailty. ESMO Open, 8 (1). 100642. ISSN 2059-7029
Brown, LC, Graham, J, Fisher, D et al. (15 more authors) (2022) Experiences of running a stratified medicine adaptive platform trial: Challenges and lessons learned from 10 years of the FOCUS4 trial in metastatic colorectal cancer. Clinical Trials, 19 (2). pp. 146-157. ISSN 1740-7745
L394
Brown, LC, Graham, J, Fisher, D et al. (15 more authors) (2022) Experiences of running a stratified medicine adaptive platform trial: Challenges and lessons learned from 10 years of the FOCUS4 trial in metastatic colorectal cancer. Clinical Trials, 19 (2). pp. 146-157. ISSN 1740-7745
L430
Platt, JR, Todd, OM orcid.org/0000-0001-7212-8095, Hall, P et al. (14 more authors) (2023) FOxTROT2: innovative trial design to evaluate the role of neoadjuvant chemotherapy for treating locally advanced colon cancer in older adults or those with frailty. ESMO Open, 8 (1). 100642. ISSN 2059-7029
MR/M016587/1
Platt, JR, Todd, OM orcid.org/0000-0001-7212-8095, Hall, P et al. (14 more authors) (2023) FOxTROT2: innovative trial design to evaluate the role of neoadjuvant chemotherapy for treating locally advanced colon cancer in older adults or those with frailty. ESMO Open, 8 (1). 100642. ISSN 2059-7029
Brown, LC, Graham, J, Fisher, D et al. (15 more authors) (2022) Experiences of running a stratified medicine adaptive platform trial: Challenges and lessons learned from 10 years of the FOCUS4 trial in metastatic colorectal cancer. Clinical Trials, 19 (2). pp. 146-157. ISSN 1740-7745
NCRN CC
Brown, LC, Graham, J, Fisher, D et al. (15 more authors) (2022) Experiences of running a stratified medicine adaptive platform trial: Challenges and lessons learned from 10 years of the FOCUS4 trial in metastatic colorectal cancer. Clinical Trials, 19 (2). pp. 146-157. ISSN 1740-7745
NIHR202395
Taze, D, Hartley, C, Morgan, AW orcid.org/0000-0003-1109-624X et al. (3 more authors) (2022) Developing consensus in Histopathology: the role of the Delphi method. Histopathology, 81 (2). pp. 159-167. ISSN 0309-0167
NOT GIVEN
Hassanieh, S., Domingo, E., Blake, A. et al. (16 more authors) (2022) 337P Prediction of poor response to oxaliplatin by an RNA signature derived and validated in colorectal cancer clinical trials. In: Annals of Oncology. ESMO Congress 2022, 09-13 Sep 2022, Paris, France. Elsevier , S691.
Seligmann, JF, Domingo, E, Fisher, D et al. (17 more authors) (2022) The clinical relevance of tumor RAS/TP53 dual mutation in early and metastatic colorectal cancer (CRC). In: 2022 ASCO Annual Meeting, 03-07 Jun 2022, Chicago, Il, USA and Online.
Williams, C. orcid.org/0000-0002-1574-653X, Seligmann, J.F. orcid.org/0000-0003-4379-6005, Guetter, C. et al. (13 more authors) (2021) Artificial intelligence-assisted immunohistochemical (IHC) evaluation of tumor amphiregulin (AREG) and epiregulin (EREG) expression as a combined predictive biomarker for panitumumab (Pan) therapy benefit in RAS wild-type (wt) metastatic colorectal cancer (mCRC): Analysis within the phase III PICCOLO trial. In: Journal of Clinical Oncology. 2021 Gastrointestinal Cancers Symposium, 15-17 Jan 2021, Online. American Society of Clinical Oncology , p. 111.
Brown, LC, Graham, J, Fisher, D et al. (15 more authors) (2022) Experiences of running a stratified medicine adaptive platform trial: Challenges and lessons learned from 10 years of the FOCUS4 trial in metastatic colorectal cancer. Clinical Trials, 19 (2). pp. 146-157. ISSN 1740-7745
Not Known
Platt, JR, Todd, OM orcid.org/0000-0001-7212-8095, Hall, P et al. (14 more authors) (2023) FOxTROT2: innovative trial design to evaluate the role of neoadjuvant chemotherapy for treating locally advanced colon cancer in older adults or those with frailty. ESMO Open, 8 (1). 100642. ISSN 2059-7029
RCCCTF-Nov21\100001
Platt, JR, Todd, OM orcid.org/0000-0001-7212-8095, Hall, P et al. (14 more authors) (2023) FOxTROT2: innovative trial design to evaluate the role of neoadjuvant chemotherapy for treating locally advanced colon cancer in older adults or those with frailty. ESMO Open, 8 (1). 100642. ISSN 2059-7029
RCS REF 08-0843 SUBCONTR
Hassanieh, S., Domingo, E., Blake, A. et al. (16 more authors) (2022) 337P Prediction of poor response to oxaliplatin by an RNA signature derived and validated in colorectal cancer clinical trials. In: Annals of Oncology. ESMO Congress 2022, 09-13 Sep 2022, Paris, France. Elsevier , S691.
Seligmann, JF, Domingo, E, Fisher, D et al. (17 more authors) (2022) The clinical relevance of tumor RAS/TP53 dual mutation in early and metastatic colorectal cancer (CRC). In: 2022 ASCO Annual Meeting, 03-07 Jun 2022, Chicago, Il, USA and Online.
Platt, JR, Todd, OM orcid.org/0000-0001-7212-8095, Hall, P et al. (14 more authors) (2023) FOxTROT2: innovative trial design to evaluate the role of neoadjuvant chemotherapy for treating locally advanced colon cancer in older adults or those with frailty. ESMO Open, 8 (1). 100642. ISSN 2059-7029
TS/S012702/1 104687
Williams, C. orcid.org/0000-0002-1574-653X, Seligmann, J.F. orcid.org/0000-0003-4379-6005, Guetter, C. et al. (13 more authors) (2021) Artificial intelligence-assisted immunohistochemical (IHC) evaluation of tumor amphiregulin (AREG) and epiregulin (EREG) expression as a combined predictive biomarker for panitumumab (Pan) therapy benefit in RAS wild-type (wt) metastatic colorectal cancer (mCRC): Analysis within the phase III PICCOLO trial. In: Journal of Clinical Oncology. 2021 Gastrointestinal Cancers Symposium, 15-17 Jan 2021, Online. American Society of Clinical Oncology , p. 111.
X120
Platt, JR, Todd, OM orcid.org/0000-0001-7212-8095, Hall, P et al. (14 more authors) (2023) FOxTROT2: innovative trial design to evaluate the role of neoadjuvant chemotherapy for treating locally advanced colon cancer in older adults or those with frailty. ESMO Open, 8 (1). 100642. ISSN 2059-7029